GLP-1 weight-loss drugs reshape healthcare economics by reducing surgeries and boosting prevention
GLP-1 weight-loss drugs like Wegovy and Zepbound are reshaping healthcare economics by reducing bariatric surgeries and improving cardiovascular outcomes; a May 2026 JAMA study shows surgeries fell about 34% as GLP-1 use rose 140%, with access and coverage debates shaping potential savings, even as next-generation meds promise more dramatic weight loss.